{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040417","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.296938+00:00","generated_at":"2026-05-24T16:37:27.441928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProKidney posts FY2024 net loss of $163.3M; FDA confirms accelerated approval path for rilparencel","bullets":["Net loss before noncontrolling interest $163.3M in 2024 vs $135.4M in 2023; R&D expenses rose 20% to $127.7M.","Cash and equivalents $358.3M at year-end; secured $140M equity to fund operations into mid-2027.","FDA confirmed accelerated approval pathway for rilparencel using eGFR slope as potential surrogate endpoint; PROACT 2 discontinued.","Full Phase 2 REGEN-007 Group 1 data expected Q2 2025; interim June 2024 showed 18-month kidney function stabilization.","Phase 3 PROACT 1 single study may support BLA; additional FDA meeting details expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040417","json":"https://secwatch.observer/filing/0000950170-25-040417.json","markdown":"https://secwatch.observer/filing/0000950170-25-040417.md","text":"https://secwatch.observer/filing/0000950170-25-040417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017025040417/0000950170-25-040417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017025040417/prok-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T16:37:27.441928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}